This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Vanda Schizophrenia Drug Gets Rotten Review

ROCKVILLE, Md. (TheStreet) -- Vanda Pharmaceuticals' (VNDA) schizophrenia drug Fanapt gets rough treatment this week from the expert authors of the newly updated psychiatrists' bible.

A negative-leaning summary of Fanapt's clinical data in schizophrenia is included for the first time in the seventh edition of the Manual of Clinical Psychopharmacology, published this week by the American Psychiatric Association.

The authors of the manual raise concerns about Fanapt's dosing, side effects and high cost compared to other drugs used to treat patients with schizophrenia.

"It is unclear to us exactly where iloperidone is going to fit in the treatment of schizophrenia," the manual's authors conclude, using the scientific name for Fanapt.

A conclusion like that in an influential psychiatric reference book is not likely to help Novartis (NVS) as it tries to sell Fanapt to doctors who have ample choices in the hyper-competitive schizophrenia drug market.

Novartis did not respond to a request for comment on the Fanapt summary in the Manual of Clinical Psychopharmacology.

Vanda developed Fanapt and got the drug approved in May 2009. In October 2009, Novartis paid Vanda $200 million for the right to sell Fanapt in the U.S. The drug was launched in January. Doctors have been slow to prescribe the Fanapt, however, according to IMS prescription tracking data.

Novartis announced first-quarter Fanapt revenue of $21 million, but wholesaler inventory stocking accounted for most of that amount. Novartis did not break out Fanapt's end-user sales from inventory stocking in its first-quarter financial report. David Moskowitz, drug analyst at Madison Williams, estimates that Novartis only sold about $1 million of Fanapt to schizophrenia patients in the first quarter based on his analysis of the IMS data.

Like Vanda, Titan Pharmaceuticals (TTNP.PK) also receives royalties based on Fanapt sales so it is similarly affected by the outcome of drug's commercial push.

The Manual of Clinical Psychopharmacology, first published in 1986, is the standard drug reference guide used by psychiatrists. The manual is written by three noted psychopharmacologists to provide clinical reviews and practical advice for the use of drugs in the treatment of psychiatric disease.

The manual's discussion of Fanapt, which belongs to the class of drugs known as second-generation antipsychotics (SGA), is not all kind.

The FDA approved Fanapt in 2009 "unexpectedly" after first rejecting the drug in 2007 due to efficacy and safety concerns, the authors state. The Fanapt entry notes two, phase III studies established Fanapt's efficacy, but then follows with a lengthy discussion of the drug's side effects and dosing issues.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs